P167 Antiplatelet agents and antaggregation therapy in the angiosuite

<h3>Introduction</h3> To provide an overview of <i>platelet physiology</i> and <i>antiaggregation/anticoagulation drugs</i> commonly administered in the angiosuite. <h3>Aim of Study</h3> Antiplatelet and anticoagulation drugs play a crucial role in neurointerventions, where the management of blood clotting is essential to prevent thromboembolic events. These medications are administered to reduce the risk of stroke and clot formation during and after neurointerventional procedures. <h3>Methods</h3> Overview of commonly administered antiplatelet and anticoagulation drugs during neurointerventions. <h3>Results</h3> 1. <b>Antiplatelet drugs:</b> a. <i>Aspirin (Acetylsalicylic Acid):</i> Aspirin inhibits platelet aggregation by irreversibly blocking the enzyme cyclooxygenase (COX). 2. <b>Anticoagulation drugs:</b> a. <i>Heparin (UFH):</i> Unfractionated heparin works by enhancing the activity of antithrombin III, inhibiting clot formation. b. <i>Aggrastat (Tirofiban):</i> Glycoprotein IIb/IIIa inhibitor. It inhibits the binding of fibrinogen and von Willebrand factor to the glycoprotein IIb/IIIa receptor, thereby preventing the final step of platelet aggregation and the formation of blood clots. c. <i>Abciximab (ReoPro):</i> Glycoprotein IIb/IIIa inhibitor, inhibition up to 15 days. <h3>Conclusion</h3> Antiplatelet therapy plays a crucial role in the angiosuite, it is thus indispensable for the angiosuite personnel to be aware of the use and mechanism of these medication. <h3>Disclosure of Interest</h3> no.